Genmab A/SGMABNASDAQ
Loading
P/E Ratio: Discounted ValuationCompressed
Percentile Rank21
3Y CAGR-17.5%
5Y CAGR-10.1%
Year-over-Year Change
Price-to-earnings ratio
3Y CAGR
-17.5%/yr
vs -4.6%/yr prior
5Y CAGR
-10.1%/yr
Recent deceleration
Acceleration
-12.9pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 19.78 | +60.9% |
| 2024 | 12.30 | -62.0% |
| 2023 | 32.34 | -8.3% |
| 2022 | 35.27 | -39.4% |
| 2021 | 58.16 | +72.4% |
| 2020 | 33.74 | -21.7% |
| 2019 | 43.07 | +1.0% |
| 2018 | 42.64 | -26.9% |
| 2017 | 58.32 | -1.4% |
| 2016 | 59.17 | - |